Intercept Pharmaceuticals Inc (ICPT) Receives Consensus Recommendation of “Hold” from Brokerages

Intercept Pharmaceuticals Inc (NASDAQ:ICPT) has been assigned a consensus rating of “Hold” from the twenty-five brokerages that are presently covering the company, Marketbeat reports. Five investment analysts have rated the stock with a sell rating, ten have issued a hold rating and ten have assigned a buy rating to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $130.88.

A number of research firms have recently issued reports on ICPT. Seaport Global Securities reiterated a “buy” rating and issued a $136.00 target price on shares of Intercept Pharmaceuticals in a research note on Friday, October 6th. JMP Securities reiterated an “outperform” rating and issued a $140.00 target price (down previously from $150.00) on shares of Intercept Pharmaceuticals in a research note on Tuesday, September 26th. Jefferies Group reiterated a “buy” rating and issued a $275.00 target price on shares of Intercept Pharmaceuticals in a research note on Wednesday, September 20th. BidaskClub cut shares of Intercept Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, December 7th. Finally, Citigroup set a $74.00 target price on shares of Intercept Pharmaceuticals and gave the company a “hold” rating in a research note on Thursday, December 21st.

A number of hedge funds have recently bought and sold shares of the stock. FMR LLC raised its position in Intercept Pharmaceuticals by 0.7% in the 2nd quarter. FMR LLC now owns 3,750,678 shares of the biopharmaceutical company’s stock worth $454,094,000 after purchasing an additional 25,958 shares during the last quarter. Carmignac Gestion raised its position in Intercept Pharmaceuticals by 0.4% in the 2nd quarter. Carmignac Gestion now owns 2,035,592 shares of the biopharmaceutical company’s stock worth $246,449,000 after purchasing an additional 7,400 shares during the last quarter. Vanguard Group Inc. raised its position in Intercept Pharmaceuticals by 4.5% in the 2nd quarter. Vanguard Group Inc. now owns 1,328,133 shares of the biopharmaceutical company’s stock worth $160,797,000 after purchasing an additional 57,149 shares during the last quarter. Senvest Management LLC bought a new position in Intercept Pharmaceuticals in the 3rd quarter worth approximately $33,883,000. Finally, First Trust Advisors LP raised its position in Intercept Pharmaceuticals by 4.5% in the 3rd quarter. First Trust Advisors LP now owns 300,455 shares of the biopharmaceutical company’s stock worth $17,438,000 after purchasing an additional 13,044 shares during the last quarter. Hedge funds and other institutional investors own 73.76% of the company’s stock.

Shares of Intercept Pharmaceuticals (NASDAQ:ICPT) opened at $54.95 on Monday. The company has a debt-to-equity ratio of 3.15, a quick ratio of 5.95 and a current ratio of 5.95. The firm has a market capitalization of $1,379.36, a P/E ratio of -3.71 and a beta of -2.05. Intercept Pharmaceuticals has a 1-year low of $52.11 and a 1-year high of $135.59.

Intercept Pharmaceuticals (NASDAQ:ICPT) last posted its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($2.89) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.48) by $0.59. Intercept Pharmaceuticals had a negative net margin of 344.74% and a negative return on equity of 176.51%. The company had revenue of $41.33 million during the quarter, compared to analysts’ expectations of $36.95 million. During the same quarter in the previous year, the company posted ($3.59) earnings per share. Intercept Pharmaceuticals’s quarterly revenue was up 697.9% compared to the same quarter last year. equities research analysts predict that Intercept Pharmaceuticals will post -13.36 EPS for the current fiscal year.

WARNING: “Intercept Pharmaceuticals Inc (ICPT) Receives Consensus Recommendation of “Hold” from Brokerages” was first published by Community Financial News and is the property of of Community Financial News. If you are reading this article on another domain, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this article can be read at https://www.com-unik.info/2018/01/15/intercept-pharmaceuticals-inc-icpt-receives-consensus-recommendation-of-hold-from-brokerages.html.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit